April 28, 2010
Posted by on
As I’m preparing for the BIO conference in Chicago next week, I’m excited to see that several of the biotech trends we’ve been following on the blog are showing up as conference sessions.
- Interested in “A New Kind of Non-Dilutive Financing and Fundraising: Partnering With Not-for-Profits”? Get an early start at our trends page on Commercialization by non-profit foundations!
- Does “Comparative Effectiveness Research and the Government Role” or “Transforming Health Care Through Personalized Medicine” catch your eye? Check out the stories we’ve highlighted on Comparative Effectiveness and Personalized Medicine!
- Of course, with the new regulatory pathway created by Health Reform legislation in the U.S., Follow-on Biologics (aka Biosimilars) are all the rage at BIO this year.
- and the whole thing kicks off with Lilly’s General Counsel speaking on “Leveraging IP to Spur Global Biotechnology Innovation, Investment and Jobs” – emphsizing the link between IP Constituencies and Global Innovation that we have been following for some time.
Stay tuned for news from these and other sessions as we hit the conference next week!
October 6, 2009
Posted by on
In updating this blog’s Trends in 2009 series for 2010, I noted that synthetic biology has garnered recent attention in The New Yorker and The Economist and it may be poised to attract more commercial attention. Here’s a great chance to get a jump on the topic…
Ontario Genomics Institute (OGI) and Integrated DNA Technologies (IDT) are hosting a free one-day symposium on synthetic biology on October 27th at MaRS. It’s invitation only, but you can contact Helen Petropoulos <hpetropoulos at ontariogenomics dot ca> if you want to register.
The symposium will be chaired by Elizabeth Edwards, a Professor in the Department of Chemical Engineering and Applied Chemistry at the University of Toronto, and presenters include leading researchers from across North America:
- Dr. Daniel Gibson, Assistant Professor, Synthetic Biology and Bioenergy, J. Craig Venter Institute
- Dr. Michael Jewett, Research Fellow in the Department of Genetics, Harvard University
- Dr. Robert Holt, Senior Scientist, Genome Sciences Centre, University of British Columbia
- Dr. Vincent Martin, Canada Research Chair in Microbial Genomics and Engineering, Concordia University
- Dr. Raymond MacDonald, Professor, Department of Molecular Biology, Southwestern Medical Center
- Dr. Scott Rose, Director of Molecular Biology Applications, Integrated DNA Technologies; and
- Kristala Jones Prather, PhD, Assistant Professor, Department of Chemical Engineering, MIT
Here’s the blurb from the organizers:
“This symposium will explore the field of synthetic biology and its many application areas, culminating in a panel discussion focused on challenges and opportunities in one of today’s most promising research fields. An open public forum on synthetic biology and its impact on society will follow the symposium program.”
Hope to see you there!
August 27, 2009
Posted by on
The organizers of the Mid-Atlantic Bio conference, which takes place November 4-6 in Washington DC, asked me to let you (oh faithful readers) know that they are looking for ”emerging companies to present to potential investors” at the conference. There’s a “showcase” track and a “growth watch” track. The application to present is here.
February 24, 2009
Posted by on
IP Osgoode just linked to the Cross-Border Biotech Blog as the “IP Pick of the Week” this week. Thanks Rex!
The Osgoode IP Law and Technology program is hosting a conference on March 20th entitled “Commercialization of innovative research: Implementing solutions that work for Canada.”
Paul Carenza, a colleague of mine at Ogilvy Renault, is speaking at the conference. You may remember Paul as the helping hand responsible for our post a few weeks ago on how *not* to cut back in difficult economic times.